September 30 marks LDL-C Awareness Day and brings both a conclusion to National Cholesterol Education Month as well as the launch of Cholesterol Connect. From the Family Heart Foundation, this novel and innovative combination of free at-home testing for blood […]
At-Home Cholesterol Screening Accessible Through New Program Read More »
The accolades for amivantamab (Rybrevant; Johnson & Johnson) use against EGFR-mutated non–small cell lung cancer (NSCLC) have been many as of late, with 3 approvals from the FDA this year alone. In March, it was approved for first-line use in
Amivantamab Accolades Add Up for NSCLC Read More »
In our podcast, “Uplifting Rural Communities,” Amy Herschell, PhD, associate vice president, Program Implementation and Evaluation, Community Care Behavioral Health Organization, and Jessica Meyers, MSEd, senior advisor for implementation, UPMC Center for High-Value Health Care, discussed the important grant-funded work
Leveraging Grants for Lasting Impact Read More »
Osimertinib (Tagrisso; AstraZeneca) received its second new indication of the year, with yesterday’s FDA approval of the irreversible third-generation tyrosine kinase inhibitor (TKI) for use among adult patients who have unresectable stage III non–small cell lung cancer (NSCLC) with EGFR
FDA Approves Osimertinib in Stage III NSCLC Read More »
